US20090145086A1 - Method for treating ophthalmic lenses - Google Patents

Method for treating ophthalmic lenses Download PDF

Info

Publication number
US20090145086A1
US20090145086A1 US12/244,333 US24433308A US2009145086A1 US 20090145086 A1 US20090145086 A1 US 20090145086A1 US 24433308 A US24433308 A US 24433308A US 2009145086 A1 US2009145086 A1 US 2009145086A1
Authority
US
United States
Prior art keywords
lens
recess
solution
package
treatment agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/244,333
Inventor
Ger M. Reynolds
Eoin Roche
Richard Connolly
John J. Cardiff
Brendan Boland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/244,333 priority Critical patent/US20090145086A1/en
Publication of US20090145086A1 publication Critical patent/US20090145086A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65BMACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B25/00Packaging other articles presenting special problems
    • B65B25/008Packaging other articles presenting special problems packaging of contact lenses
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29DPRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D11/00Producing optical elements, e.g. lenses or prisms
    • B29D11/00009Production of simple or compound lenses
    • B29D11/00038Production of contact lenses
    • B29D11/00067Hydrating contact lenses

Definitions

  • This invention provides a method for treating ophthalmic lenses in its package with an organic surface treatment agent.
  • the surfaces of the lenses may be rendered more biocompatible, for the purpose of reducing or eliminating epithelial cell growth on the lens.
  • intraocular lenses are often placed in the eye with an intraocular lens inserter which has surfaces that contact the lens while it is extruded against these surfaces; the lens surfaces may be modified to become more lubricious so as to lower the coefficient of friction for contacting the lens inserted.
  • the lens surfaces may be made more wettable by tear film or less resistant to protein and/or lipid deposits from tear film, and more comfortable during wear.
  • the lens surfaces have a higher tendency to be hydrophobic with lower wettability, so often a surface treatment is desirable to increase the surface wettability is desired.
  • Various methods of changing the surface characteristics of ophthalmic lenses are known that involve attaching a treatment agent to the lens surfaces.
  • a conventional manner of packaging ophthalmic lenses, especially contact lenses, is in a so-called blister package.
  • Such packages include a recess designed to hold an individual lens, which is typically immersed in a saline packaging solution.
  • the packages are then enclosed and sealed with lidstock, the lidstock conventionally being a metallic laminate that can withstand post-packaging heat sterilization conditions.
  • the packaging solution may include various agents.
  • packaging solutions for blister packages have sometimes been formulated to reduce or eliminate lens folding and sticking. For this reason, polyvinyl alcohol (PVA) has been used in contact lens packaging solutions.
  • PVA polyvinyl alcohol
  • U.S. Pat. No. 6,440,366 discloses contact lens packaging solutions comprising polyethylene oxide (PEO)/polypropylene oxide (PPO) block copolymers, especially poloxamers or poloxamines.
  • Known blister packages include recesses that are concave, recesses that are flat-bottomed, and recesses that are partially concave with a flat bottom.
  • a blister package with a flat bottom having four parallel, longitudinal grooves therein which is used to package various contact lenses sold by Bausch & Lomb Incorporated (Rochester, N.Y., USA).
  • Bausch & Lomb Incorporated Bausch & Lomb Incorporated (Rochester, N.Y., USA).
  • Other specific examples may be found in U.S. Pat. Nos. 5,842,325; 5,722,536; 5,467,868; 2004/0031701; 2004/0004008; 2002/0046958; 6,072,172; 5,143,660; and 6,889,825.
  • This invention provides of a method of treating an ophthalmic lens in a package, comprising: placing the lens and an aqueous solution in a recess of package, the solution comprising an organic surface treatment agent that attaches to anterior and posterior surfaces of the lens; and sealing the recess of the package with lidstock and sterilizing the package contents; wherein a bottom of the recess includes raised projections.
  • This invention recognized that it may be desirable to effect attachment of the treatment agent to the lens surfaces while the lens is contained in a package, for example, to reduce material handling steps and the accompanying costs associated therewith. And if one employs a solution, containing the treatment agent, that is ophthalmically compatible, this solution may serve as the final packaging solution, and the heat sterilization of the package and its contents can serve to effect chemical attachment of the treatment agent to the lens surfaces.
  • FIG. 1 is a top perspective view of a first embodiment of a lens blister package suitable for the method of this invention.
  • FIG. 2 is a bottom perspective view of the lens blister package of FIG. 1 .
  • FIG. 3 is a top plan view of the lens blister package of FIG. 1 .
  • FIG. 4 is a cross-sectional view of the lens blister package of FIG. 1 , taken along line B-B of FIG. 3 .
  • FIG. 5 is a top plan view of a second embodiment of a lens blister package suitable for the method of this invention.
  • FIG. 6 is a top plan view of a third embodiment of a lens blister package suitable for the method of this invention.
  • FIG. 7 is a cross-section view of the lens blister package of FIG. 6 , taken along line C-C.
  • FIG. 8 is a top plan view of a fourth embodiment of a lens blister package suitable for the method of this invention.
  • FIG. 9 is a cross-section view of the lens blister package of FIG. 8 , taken along line D-D.
  • This invention provides a method of treating an ophthalmic lens in a package.
  • the method comprises: placing the lens and an aqueous solution in a recess of package, the solution comprising an organic surface treatment agent that attaches to anterior and posterior surfaces of the lens; and sealing the recess of the package with lidstock and sterilizing the package contents; wherein a bottom of the recess includes raised projections.
  • ophthalmic lens means a lens intended for direct contact with ophthalmic tissue, including contact lenses and intraocular lenses.
  • contact lenses including contact lenses and intraocular lenses.
  • the process is discussed with particular reference to silicone hydrogel contact lenses, a preferred embodiment of this invention, but the invention may be employed for surface treating other polymeric biomedical devices.
  • Hydrogels comprise a hydrated, crosslinked polymeric system containing water in an equilibrium state. Accordingly, hydrogels are copolymers prepared from hydrophilic monomers.
  • the hydrogel copolymers are generally prepared by polymerizing a mixture containing at least one lens-forming silicone-containing monomer and at least one lens-forming hydrophilic monomer. Either the silicone-containing monomer or the hydrophilic monomer may function as a crosslinking agent (a crosslinking agent being defined as a monomer having multiple polymerizable functionalities), or alternately, a separate crosslinking agent may be employed in the initial monomer mixture from which the hydrogel copolymer is formed.
  • a crosslinking agent being defined as a monomer having multiple polymerizable functionalities
  • Silicone hydrogels typically have a water content between about 10 to about 80 weight percent.
  • Examples of useful lens-forming hydrophilic monomers include: amides such as N,N-dimethylacrylamide and N,N-dimethylmethacrylamide; cyclic lactams such as N-vinyl-2-pyrrolidone; (meth)acrylated alcohols, such as 2-hydroxyethyl methacrylate, 2-hydroxyethyl acrylate and glyceryl methacrylate; (meth)acrylated poly(ethylene glycol)s; (meth)acrylic acids such as methacrylic acid and acrylic acid; and azlactone-containing monomers, such as 2-isopropenyl-4,4-dimethyl-2-oxazolin-5-one and 2-vinyl-4,4-dimethyl-2-oxazolin-5-one.
  • amides such as N,N-dimethylacrylamide and N,N-dimethylmethacrylamide
  • cyclic lactams such as N-vinyl-2-pyrrolidone
  • (meth)” denotes an optional methyl substituent.
  • terms such as “(meth)acrylate” denotes either methacrylate or acrylate
  • “(meth)acrylic acid” denotes either methacrylic acid or acrylic acid.
  • hydrophilic vinyl carbonate or vinyl carbamate monomers disclosed in U.S. Pat. No. 5,070,215
  • hydrophilic oxazolone monomers disclosed in U.S. Pat. No. 4,910,277, the disclosures of which are incorporated herein by reference.
  • Other suitable hydrophilic monomers will be apparent to one skilled in the art.
  • silicone-containing monomers examples include bulky polysiloxanylalkyl(meth)acrylic monomers.
  • An example of such monofunctional, bulky polysiloxanylalkyl(meth)acrylic monomers are represented by the following Formula I:
  • X denotes —O— or —NR—
  • each R 1 independently denotes hydrogen or methyl
  • each R 2 independently denotes a lower alkyl radical, phenyl radical or a group represented by
  • each R 2 ′ independently denotes a lower alkyl or phenyl radical; and h is 1 to 10.
  • One preferred bulky monomer is 3-methacryloxypropyl tris(trimethyl-siloxy)silane or tris(trimethylsiloxy)silylpropyl methacrylate, sometimes referred to as TRIS.
  • silicone-containing monomers includes silicone-containing vinyl carbonate or vinyl carbamate monomers such as: 1,3-bis[4-vinyloxycarbonyloxy)but-1-yl]tetramethyldisiloxane; 1,3-bis[4-vinyloxycarbonyloxy)but-1-yl]polydimethylsiloxane; 3-(trimethylsilyl)propyl vinyl carbonate; 3-(vinyloxycarbonylthio)propyl[tris(trimethylsiloxy)silane]; 3-[tris(trimethylsiloxy)silyl]propyl vinyl carbamate; 3-[tris(trimethylsiloxy)silyl]propyl allyl carbamate; 3-[tris(trimethylsiloxy)silyl]propyl vinyl carbonate; t-butyldimethylsiloxyethyl vinyl carbonate; trimethylsilylethyl vinyl carbonate; and trimethylsilylmethyl vinyl carbonate.
  • silicone-containing vinyl carbonate or vinyl carbamate monomers are represented by Formula II:
  • Y′ denotes —O—, —S— or —NH—
  • R Si denotes a silicone-containing organic radical
  • R 3 denotes hydrogen or methyl
  • d is 1, 2, 3 or 4; and q is 0 or 1.
  • Suitable silicone-containing organic radicals R Si include the following:
  • p′ is 1 to 6;
  • R 5 denotes an alkyl radical or a fluoroalkyl radical having 1 to 6 carbon atoms
  • silicone-containing monomers includes polyurethane-polysiloxane macromonomers (also sometimes referred to as prepolymers), which may have hard-soft-hard blocks like traditional urethane elastomers.
  • silicone urethane monomers are represented by Formulae IV and V:
  • D denotes an alkyl diradical, an alkyl cycloalkyl diradical, a cycloalkyl diradical, an aryl diradical or an alkylaryl diradical having 6 to 30 carbon atoms;
  • G denotes an alkyl diradical, a cycloalkyl diradical, an alkyl cycloalkyl diradical, an aryl diradical or an alkylaryl diradical having 1 to 40 carbon atoms and which may contain ether, thio or amine linkages in the main chain;
  • a is at least 1;
  • A denotes a divalent polymeric radical of Formula VI:
  • each R s independently denotes an alkyl or fluoro-substituted alkyl group having 1 to 10 carbon atoms which may contain ether linkages between carbon atoms;
  • n′ is at least 1;
  • p is a number which provides a moiety weight of 400 to 10,000;
  • each of E and E′ independently denotes a polymerizable unsaturated organic radical represented by Formula VII:
  • R 6 is hydrogen or methyl
  • R 7 is hydrogen, an alkyl radical having 1 to 6 carbon atoms, or a —CO—Y—R 9 radical wherein Y is —O—, —S— or —NH—;
  • R 8 is a divalent alkylene radical having 1 to 10 carbon atoms
  • R 9 is a alkyl radical having 1 to 12 carbon atoms
  • X denotes —CO— or —OCO—
  • Z denotes —O— or —NH—
  • Ar denotes an aromatic radical having 6 to 30 carbon atoms
  • w is 0 to 6; x is 0 or 1; y is 0 or 1; and z is 0 or 1.
  • m is at least 1 and is preferably 3 or 4
  • a is at least 1 and preferably is 1
  • p is a number which provides a moiety weight of 400 to 10,000 and is preferably at least 30
  • R 10 is a diradical of a diisocyanate after removal of the isocyanate group, such as the diradical of isophorone diisocyanate
  • each E′′ is a group represented by:
  • a preferred silicone hydrogel material comprises (based on the initial monomer mixture that is copolymerized to form the hydrogel copolymeric material) 5 to 50 percent, preferably 10 to 25, by weight of one or more silicone macromonomers, 5 to 75 percent, preferably 30 to 60 percent, by weight of one or more polysiloxanylalkyl (meth)acrylic monomers, and 10 to 50 percent, preferably 20 to 40 percent, by weight of a hydrophilic monomer.
  • the silicone macromonomer is a poly(organosiloxane) capped with an unsaturated group at two or more ends of the molecule.
  • the silane macromonomer is a silicone-containing vinyl carbonate or vinyl carbamate or a polyurethane-polysiloxane having one or more hard-soft-hard blocks and end-capped with a hydrophilic monomer.
  • contact lens materials for which the present invention is useful are taught in U.S. Pat. No. 6,891,010 (Kunzler et al.); U.S. Pat. No. 5,908,906 (Kunzler et al.); U.S. Pat. No. 5,714,557 (Kunzler et al.); U.S. Pat. No. 5,710,302 (Kunzler et al.); U.S. Pat. No. 5,708,094 (Lai et al.); U.S. Pat. No. 5,616,757 (Bambury et al.); U.S. Pat. No. 5,610,252 (Bambury et al.); U.S. Pat. No.
  • the monomer mixtures may be charged to a mold, and then subjected to heat and/or light radiation, such as UV radiation, to effect curing, or free radical polymerization, of the monomer mixture in the mold.
  • heat and/or light radiation such as UV radiation
  • the monomer mixtures may be cast in the shape of rods or buttons, which are then lathe cut into a desired shape, for example, into a lens-shaped article.
  • extractables include any remaining diluent, unreacted monomers, and oligomers formed from side reactions of the monomers.
  • the lens is hydrated, either as part of the extraction process, or in a separate subsequent operation.
  • the lens is hydrated to replace the organic solvent with water or aqueous solution. Hydration may be performed while the lens is held in its package, or prior to placing the lens in the package. In any event, ultimately, the lens is contained in the package with an aqueous packaging solution.
  • This invention recognized the desirability of effecting attachment of the treatment agent to the lens surfaces while the lens is contained in a package, in contrast to effecting attachment prior to placing the lens in the package. This offers a reduction in material handling steps and the accompanying costs associated therewith. Also, if the solution containing the treatment agent is ophthalmically compatible, this solution may serve as the final packaging solution, and the heat sterilization of the package and its contents can serve to effect chemical attachment of the treatment agent to the lens surfaces.
  • attachment of the treatment agent to the lens surface, and like terms, denotes that the treatment agent is substantially adhered to the lens surfaces. Thus, after a single rinsing with water of the lens surfaces with the treatment agent attached thereto, at least 50% of the treatment agent will remain adhered to the lens surfaces.
  • the surface treatment agent is attached to the lens surfaces by at least one of covalent bonding, ionic attachment, and hydrogen bonding.
  • Covalent bonding denotes that a chemical reaction occurs between the treatment agent and the lens surface, so that covalent bonds are formed therebetween.
  • Ionic attachment denotes that the lens surfaces are ionically charged, and the organic surface treatment agent contains moieties with an opposite, ionic charge.
  • the lens surfaces may be anionic charged, and the treatment agent may be cationic or zwitterionic, that interacts with the anionic lens surface.
  • organic surface treatment agents may be employed, including treatment agents known in the art.
  • this invention is applicable for the organic surface treatment agents described in U.S. Pat. No. 7,083,646, the entire disclosure of which is incorporated herein by reference.
  • this method involves surface modification of medical devices, particularly ophthalmic lenses, with one or more reactive, hydrophilic polymers as the surface treatment agent.
  • the reactive, hydrophilic polymers are copolymers of at least one hydrophilic monomer and at least one monomer that contains reactive chemical functionality.
  • the hydrophilic monomers can be aprotic types such as N,N-dimethylacrylamide and N-vinylpyrrolidone, or protic types such as methacrylic acid and 2-hydroxyethyl methacrylate.
  • the monomer containing reactive chemical functionality can be an epoxide-containing monomer, such as glycidyl methacrylate.
  • the hydrophilic monomer and the monomer containing reactive chemical functionality are copolymerized at a desired molar ratio thereof.
  • the hydrophilic monomer serves to render the resultant copolymer hydrophilic.
  • the monomer containing reactive chemical functionality provides a reactive group that can react with the lens surface. In other words, this resultant copolymer contains the reactive chemical functionality that can react with complementary functional groups at or near the lens surface, and form covalent bonds therewith.
  • this invention is applicable for the organic surface treatment agents described in US 2007/0122540, the entire disclosure of which is incorporated herein by reference.
  • this method involves surface modification of medical devices, particularly ophthalmic lenses, where reactive surfactants as the surface treatment agent are covalently bound to the lens surfaces.
  • Preferred reactive surfactants are functionalized poloxamers or functionalized poloxamines having reactive functionality that is complimentary to surface functionality of the ophthalmic lens.
  • Representative functionalized surfactants are those containing epoxide, methacrylate, or isocyanate functionalities, such as represented below.
  • the reactive groups of the treatment agent are matched with the reactive groups on the lens surface.
  • the lens surfaces contain carboxylic acid groups
  • a glycidyl group can be a reactive group of the surface treatment agent.
  • an isocyanate group or carbonyl chloride group can be a reactive group of the surface treatment agent.
  • suitable lens-forming monomers providing reactive groups on the lens surface
  • suitable lens-forming monomers include those having hydroxy functional groups, such as 2-hydroxyethyl methacrylate, glyceryl methacrylate and 3-hydroxypropyl methacrylamide.
  • suitable lens-forming monomers providing the lens surfaces with carboxylic acid reactive groups include methacrylic acid, acrylic acid and N-carboxy- ⁇ -alanine-N-vinyl ester.
  • suitable lens-forming monomers providing the lens surface with oxazolinone reactive groups include 2-isopropenyl-4,4-dimethyl-2-oxazolin-5-one, 2-vinyl-4,4-dimethyl-2-oxazolin-5-one, spiro-4′-(2′-isopropenyl-2′-oxazolin-5-one)cyclohexane, spiro-4′-(2′-vinyl-2′-oxazolin-5′-one)cyclohexane and 2-(1-propenyl)-4,4-dimethyl-oxazolin-5-one.
  • suitable lens-forming monomers providing the lens surface with anhydride functional groups include methacrylic anhydride, maleic anhydride and acrylic anhydride.
  • An example of a suitable lens-forming monomer providing the lens surfaces with epoxide reactive groups includes glycidyl methacrylate.
  • the surface treatment agent may be one as employed in the method described in U.S. Pat. No. 6,428,839 (Kunzler et al.), the entire disclosure of which is incorporated herein by reference.
  • this method employs poly(acrylic)acid (PAA) surface complexation.
  • PAA poly(acrylic)acid
  • Hydrogel contact lens copolymers containing polymerized hydrophilic lens-forming monomers having relatively strong proton donating moieties, for example DMA or NVP are treated with water-based solutions containing PAA or PAA co-polymers, acting as wetting agents, to render a lubricious, stable, highly wettable PAA-based surface coating.
  • PAA-containing agents may be employed, although generally, coating materials containing carboxylic acid functionality are preferred.
  • Surface treatment agents include poly(vinylpyrrolidinone(VP)-co-acrylic acid(AA)), poly(methylvinylether-alt-maleic acid), poly(acrylic acid-graft-ethyleneoxide), poly(AA-co-methacrylic acid), poly(acrylamide-co-AA), poly(AA-co-maleic), and poly(butadiene-maleic acid).
  • Particularly preferred polymers are characterized by acid contents of at least about 30 mole percent, preferably at least about 40 mole percent.
  • the lens, with its surface in contact with the PAA-containing solution may be heated by autoclaving, or subjected to microwave radiation, to facilitate attachment of the PAA to the lens surface.
  • this solution also serves as the final packaging solution, and this solution is ophthalmically compatible. Then, when the package contents are heat sterilized, this heat treatment can serve to effect chemical attachment of the treatment agent to the lens surfaces, if needed. Any excess treatment agent, not attached to the lens surfaces, remains in the final packaging solution.
  • this solution is removed with a portion of the organic treatment agent remaining attached to the lens surface. Any excess treatment agent is removed with the solution. If heat treatment is needed to effect chemical attachment of the treatment agent to the lens surfaces, the heat treatment is performed prior to removing this solution from the package recess. Subsequently, after removing this solution, an aqueous packaging solution is added to the recess, followed by sealing the recess with lidstock and sterilizing the package contents.
  • the final packaging solution is an aqueous solution, preferably a saline solution. having a pH value within the range of about 6 to about 8, and preferably about 6.5 to about 7.8.
  • Suitable buffers may be included, such as: phosphate; borate; citrate; carbonate; tris-(hydroxymethyl)aminomethane (TRIS); bis(2-hydroxyethyl)-imino-tris-(hydroxymethyl)aminoalcohol (bis-tris); zwitterionic buffers such as N-[2-Hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine (Tricine)and N-[2-Hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine, MOPS; N-(Carbamoylmethyl)taurine (ACES); amino acids and amino acid derivatives; and mixtures thereof.
  • TriS tris-(hydroxymethyl)aminomethane
  • bis-tris bis(2-hydroxyethyl)
  • buffers will be used in amounts ranging from about 0.05 to about 2.5 percent by weight, and preferably from about 0.1 to about 1.5 percent by weight of the solution.
  • the solutions of the present invention may be adjusted with tonicity agents, to approximate the osmotic pressure of normal lacrimal fluids, which is equivalent to a 0.9 percent solution of sodium chloride or 2.5 percent of glycerol solution.
  • the solutions are made substantially isotonic with physiological saline used alone or in combination, otherwise if simply blended with sterile water and made hypotonic or made hypertonic the lenses will lose their desirable optical parameters.
  • excess saline may result in the formation of a hypertonic solution, which will cause stinging, and eye irritation.
  • Suitable tonicity adjusting agents include, but are not limited to, sodium and potassium chloride, dextrose, calcium and magnesium chloride and the like and mixtures thereof. These agents are typically used individually in amounts ranging from about 0.01 to about 2.5% w/v and preferably from about 0.2 to about 1.5% w/v.
  • the tonicity agent will be employed in an amount to provide a final osmotic value of at least about 200 mOsm/kg, preferably from about 200 to about 450 mOsm/kg, more preferably from about 250 to about 400 mOsm/kg, and most preferably from about 280 to about 370 mOsm/kg.
  • FIGS. 1 to 9 Representative blister packages that may be employed in the method of this invention are illustrated in FIGS. 1 to 9 .
  • FIGS. 1 to 4 illustrate a first embodiment of a blister package.
  • Package 1 includes a substrate 3 including recess 2 formed therein, recess 2 sized and configured to hold an individual contact lens 5 therein.
  • recess 2 is a concave recess with a flat bottom 6 .
  • Bottom 6 includes three parallel, longitudinal ridges 7 thereon. Ridges 7 preferably have a height of at least 0.2 mm, more preferably at least 0.4 mm.
  • the anterior surface of contact lens 5 rests on at least one of ridges 7 when the package is oriented as in FIG. 4 . Without these ridges, the anterior lens surface would rest on flat bottom 6 , which could lead to non-uniform coating of the contact lens, especially this anterior surface of the lens.
  • contact lens 5 is contained in recess 2 and immersed in solution.
  • Recess 2 is then sealed with lidstock, i.e., by sealing the lidstock with heat to raised surface 9 .
  • the package and its contents may now be sterilized, preferably by heat sterilization such as autoclaving.
  • Recess 2 has a depth greater than a height of the lens, and a sufficiently large volume, that the lens is completely immersed in the final packaging solution.
  • FIG. 5 illustrates a second embodiment of a blister package.
  • Package 11 includes a substrate 13 including recess 12 formed therein.
  • recess 12 has a somewhat oval-shaped flat bottom 16 , and the bottom includes four longitudinal ridges 17 thereon.
  • FIGS. 6 and 7 illustrates a third embodiment of a blister package.
  • Package 21 includes a substrate 23 including recess 22 formed therein.
  • recess 22 is a concave recess, i.e., a rounded bowl shape.
  • the bottom includes five parallel, longitudinal ridges 27 thereon.
  • FIGS. 8 and 9 illustrates a fourth embodiment of a blister package.
  • Package 31 includes a substrate 33 including recess 32 formed therein.
  • recess 32 is a concave recess, i.e., a rounded bowl shape, with multiple raised, dot-like protrusions thereon.
  • the recess is then sealed with lidstock, i.e., by sealing the lidstock with heat.
  • the lidstock is sealed to raised surface 9 in FIGS. 1 to 4 .
  • the package and its contents may now be sterilized, preferably by heat sterilization such as autoclaving.
  • the recess has a depth greater than a height of the lens, and a sufficiently large volume, that the lens is completely immersed in the final packaging solution.
  • the recess is filed with at least 0.5 ml of final packaging solution, more preferably at least 1 ml, and most preferably at least 1.2 ml.

Abstract

A method of treating an ophthalmic lens in a package involves: placing the lens and an aqueous solution in a recess of package, the solution including an organic surface treatment agent that attaches to anterior and posterior surfaces of the lens; and sealing the recess of the package with lidstock and sterilizing the package contents. The bottom of the recess includes raised projections.

Description

    BACKGROUND OF THE INVENTION
  • This application claims benefit of provisional patent application No. 61/012,855 filed on Dec. 11, 2007 which is incorporated by reference herein.
  • This invention provides a method for treating ophthalmic lenses in its package with an organic surface treatment agent.
  • It is often desired to improve the surface characteristics of an ophthalmic lens. For example, in the case of intraocular lenses, the surfaces of the lenses may be rendered more biocompatible, for the purpose of reducing or eliminating epithelial cell growth on the lens. Also, intraocular lenses are often placed in the eye with an intraocular lens inserter which has surfaces that contact the lens while it is extruded against these surfaces; the lens surfaces may be modified to become more lubricious so as to lower the coefficient of friction for contacting the lens inserted. In the case of contact lenses, the lens surfaces may be made more wettable by tear film or less resistant to protein and/or lipid deposits from tear film, and more comfortable during wear. With respect to silicon-containing lenses, the lens surfaces have a higher tendency to be hydrophobic with lower wettability, so often a surface treatment is desirable to increase the surface wettability is desired. Various methods of changing the surface characteristics of ophthalmic lenses are known that involve attaching a treatment agent to the lens surfaces.
  • A conventional manner of packaging ophthalmic lenses, especially contact lenses, is in a so-called blister package. Such packages include a recess designed to hold an individual lens, which is typically immersed in a saline packaging solution. The packages are then enclosed and sealed with lidstock, the lidstock conventionally being a metallic laminate that can withstand post-packaging heat sterilization conditions. The packaging solution may include various agents. As one example, because the lens material may tend to stick to itself and to the lens package, packaging solutions for blister packages have sometimes been formulated to reduce or eliminate lens folding and sticking. For this reason, polyvinyl alcohol (PVA) has been used in contact lens packaging solutions. Additionally, U.S. Pat. No. 6,440,366 discloses contact lens packaging solutions comprising polyethylene oxide (PEO)/polypropylene oxide (PPO) block copolymers, especially poloxamers or poloxamines.
  • Various blister packages are known. Known blister packages include recesses that are concave, recesses that are flat-bottomed, and recesses that are partially concave with a flat bottom. One specific example is a blister package with a flat bottom having four parallel, longitudinal grooves therein, which is used to package various contact lenses sold by Bausch & Lomb Incorporated (Rochester, N.Y., USA). Other specific examples may be found in U.S. Pat. Nos. 5,842,325; 5,722,536; 5,467,868; 2004/0031701; 2004/0004008; 2002/0046958; 6,072,172; 5,143,660; and 6,889,825.
  • SUMMARY OF THE INVENTION
  • This invention provides of a method of treating an ophthalmic lens in a package, comprising: placing the lens and an aqueous solution in a recess of package, the solution comprising an organic surface treatment agent that attaches to anterior and posterior surfaces of the lens; and sealing the recess of the package with lidstock and sterilizing the package contents; wherein a bottom of the recess includes raised projections.
  • This invention recognized that it may be desirable to effect attachment of the treatment agent to the lens surfaces while the lens is contained in a package, for example, to reduce material handling steps and the accompanying costs associated therewith. And if one employs a solution, containing the treatment agent, that is ophthalmically compatible, this solution may serve as the final packaging solution, and the heat sterilization of the package and its contents can serve to effect chemical attachment of the treatment agent to the lens surfaces.
  • However, problems were encountered in that the surfaces of the lens were not uniformly coated with the treatment agent, especially the lens surface in contact with the recess bottom. These problems may be overcome by employing packages with recesses including raised projections on the bottoms thereof, to ensure better flow of the solution around the lens surfaces.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a top perspective view of a first embodiment of a lens blister package suitable for the method of this invention.
  • FIG. 2 is a bottom perspective view of the lens blister package of FIG. 1.
  • FIG. 3 is a top plan view of the lens blister package of FIG. 1.
  • FIG. 4 is a cross-sectional view of the lens blister package of FIG. 1, taken along line B-B of FIG. 3.
  • FIG. 5 is a top plan view of a second embodiment of a lens blister package suitable for the method of this invention.
  • FIG. 6 is a top plan view of a third embodiment of a lens blister package suitable for the method of this invention.
  • FIG. 7 is a cross-section view of the lens blister package of FIG. 6, taken along line C-C.
  • FIG. 8 is a top plan view of a fourth embodiment of a lens blister package suitable for the method of this invention.
  • FIG. 9 is a cross-section view of the lens blister package of FIG. 8, taken along line D-D.
  • DETAILED DESCRIPTION OF VARIOUS PREFERRED EMBODIMENTS
  • This invention provides a method of treating an ophthalmic lens in a package. The method comprises: placing the lens and an aqueous solution in a recess of package, the solution comprising an organic surface treatment agent that attaches to anterior and posterior surfaces of the lens; and sealing the recess of the package with lidstock and sterilizing the package contents; wherein a bottom of the recess includes raised projections.
  • The term “ophthalmic lens” means a lens intended for direct contact with ophthalmic tissue, including contact lenses and intraocular lenses. In the following description, the process is discussed with particular reference to silicone hydrogel contact lenses, a preferred embodiment of this invention, but the invention may be employed for surface treating other polymeric biomedical devices.
  • Hydrogels comprise a hydrated, crosslinked polymeric system containing water in an equilibrium state. Accordingly, hydrogels are copolymers prepared from hydrophilic monomers. In the case of silicone hydrogels, the hydrogel copolymers are generally prepared by polymerizing a mixture containing at least one lens-forming silicone-containing monomer and at least one lens-forming hydrophilic monomer. Either the silicone-containing monomer or the hydrophilic monomer may function as a crosslinking agent (a crosslinking agent being defined as a monomer having multiple polymerizable functionalities), or alternately, a separate crosslinking agent may be employed in the initial monomer mixture from which the hydrogel copolymer is formed. (As used herein, the term “monomer” or “monomeric” and like terms denote relatively low molecular weight compounds that are polymerizable by free radical polymerization, as well as higher molecular weight compounds also referred to as “prepolymers”, “macromonomers”, and related terms.) Silicone hydrogels typically have a water content between about 10 to about 80 weight percent.
  • Examples of useful lens-forming hydrophilic monomers include: amides such as N,N-dimethylacrylamide and N,N-dimethylmethacrylamide; cyclic lactams such as N-vinyl-2-pyrrolidone; (meth)acrylated alcohols, such as 2-hydroxyethyl methacrylate, 2-hydroxyethyl acrylate and glyceryl methacrylate; (meth)acrylated poly(ethylene glycol)s; (meth)acrylic acids such as methacrylic acid and acrylic acid; and azlactone-containing monomers, such as 2-isopropenyl-4,4-dimethyl-2-oxazolin-5-one and 2-vinyl-4,4-dimethyl-2-oxazolin-5-one. (As used herein, the term “(meth)” denotes an optional methyl substituent. Thus, terms such as “(meth)acrylate” denotes either methacrylate or acrylate, and “(meth)acrylic acid” denotes either methacrylic acid or acrylic acid.) Still further examples are the hydrophilic vinyl carbonate or vinyl carbamate monomers disclosed in U.S. Pat. No. 5,070,215, and the hydrophilic oxazolone monomers disclosed in U.S. Pat. No. 4,910,277, the disclosures of which are incorporated herein by reference. Other suitable hydrophilic monomers will be apparent to one skilled in the art.
  • Applicable silicone-containing monomeric materials for use in the formation of silicone hydrogels are well known in the art and numerous examples are provided in U.S. Pat. Nos. 4,136,250; 4,153,641; 4,740,533; 5,034,461; 5,070,215; 5,260,000; 5,310,779; and 5,358,995.
  • Examples of applicable silicone-containing monomers include bulky polysiloxanylalkyl(meth)acrylic monomers. An example of such monofunctional, bulky polysiloxanylalkyl(meth)acrylic monomers are represented by the following Formula I:
  • Figure US20090145086A1-20090611-C00001
  • wherein:
  • X denotes —O— or —NR—;
  • each R1 independently denotes hydrogen or methyl;
  • each R2 independently denotes a lower alkyl radical, phenyl radical or a group represented by
  • Figure US20090145086A1-20090611-C00002
  • wherein each R2′ independently denotes a lower alkyl or phenyl radical; and h is 1 to 10. One preferred bulky monomer is 3-methacryloxypropyl tris(trimethyl-siloxy)silane or tris(trimethylsiloxy)silylpropyl methacrylate, sometimes referred to as TRIS.
  • Another class of representative silicone-containing monomers includes silicone-containing vinyl carbonate or vinyl carbamate monomers such as: 1,3-bis[4-vinyloxycarbonyloxy)but-1-yl]tetramethyldisiloxane; 1,3-bis[4-vinyloxycarbonyloxy)but-1-yl]polydimethylsiloxane; 3-(trimethylsilyl)propyl vinyl carbonate; 3-(vinyloxycarbonylthio)propyl[tris(trimethylsiloxy)silane]; 3-[tris(trimethylsiloxy)silyl]propyl vinyl carbamate; 3-[tris(trimethylsiloxy)silyl]propyl allyl carbamate; 3-[tris(trimethylsiloxy)silyl]propyl vinyl carbonate; t-butyldimethylsiloxyethyl vinyl carbonate; trimethylsilylethyl vinyl carbonate; and trimethylsilylmethyl vinyl carbonate.
  • An example of silicone-containing vinyl carbonate or vinyl carbamate monomers are represented by Formula II:
  • Figure US20090145086A1-20090611-C00003
  • wherein:
  • Y′ denotes —O—, —S— or —NH—;
  • RSi denotes a silicone-containing organic radical;
  • R3 denotes hydrogen or methyl;
  • d is 1, 2, 3 or 4; and q is 0 or 1.
  • Suitable silicone-containing organic radicals RSi include the following:
  • Figure US20090145086A1-20090611-C00004
  • wherein:
  • R4 denotes
  • Figure US20090145086A1-20090611-C00005
  • wherein p′ is 1 to 6;
  • R5 denotes an alkyl radical or a fluoroalkyl radical having 1 to 6 carbon atoms;
  • e is 1 to 200; n′ is 1, 2, 3 or 4; and m′ is 0, 1, 2, 3, 4 or 5.
  • An example of a particular species within Formula II is represented by Formula III:
  • Figure US20090145086A1-20090611-C00006
  • Another class of silicone-containing monomers includes polyurethane-polysiloxane macromonomers (also sometimes referred to as prepolymers), which may have hard-soft-hard blocks like traditional urethane elastomers. Examples of silicone urethane monomers are represented by Formulae IV and V:

  • E(*D*A*D*G)a*D*A*D*E′; or   (IV)

  • E(*D*G*D*A)a*D*G*D*E′;   (V)
  • wherein:
  • D denotes an alkyl diradical, an alkyl cycloalkyl diradical, a cycloalkyl diradical, an aryl diradical or an alkylaryl diradical having 6 to 30 carbon atoms;
  • G denotes an alkyl diradical, a cycloalkyl diradical, an alkyl cycloalkyl diradical, an aryl diradical or an alkylaryl diradical having 1 to 40 carbon atoms and which may contain ether, thio or amine linkages in the main chain;
  • * denotes a urethane or ureido linkage;
  • a is at least 1;
  • A denotes a divalent polymeric radical of Formula VI:
  • Figure US20090145086A1-20090611-C00007
  • wherein:
  • each Rs independently denotes an alkyl or fluoro-substituted alkyl group having 1 to 10 carbon atoms which may contain ether linkages between carbon atoms;
  • m′ is at least 1; and
  • p is a number which provides a moiety weight of 400 to 10,000;
  • each of E and E′ independently denotes a polymerizable unsaturated organic radical represented by Formula VII:
  • Figure US20090145086A1-20090611-C00008
  • wherein:
  • R6 is hydrogen or methyl;
  • R7 is hydrogen, an alkyl radical having 1 to 6 carbon atoms, or a —CO—Y—R9 radical wherein Y is —O—, —S— or —NH—;
  • R8 is a divalent alkylene radical having 1 to 10 carbon atoms;
  • R9 is a alkyl radical having 1 to 12 carbon atoms;
  • X denotes —CO— or —OCO—;
  • Z denotes —O— or —NH—;
  • Ar denotes an aromatic radical having 6 to 30 carbon atoms;
  • w is 0 to 6; x is 0 or 1; y is 0 or 1; and z is 0 or 1.
  • A more specific example of a silicone-containing urethane monomer is represented by Formula (VIII):
  • Figure US20090145086A1-20090611-C00009
  • wherein m is at least 1 and is preferably 3 or 4, a is at least 1 and preferably is 1, p is a number which provides a moiety weight of 400 to 10,000 and is preferably at least 30, R10 is a diradical of a diisocyanate after removal of the isocyanate group, such as the diradical of isophorone diisocyanate, and each E″ is a group represented by:
  • Figure US20090145086A1-20090611-C00010
  • A preferred silicone hydrogel material comprises (based on the initial monomer mixture that is copolymerized to form the hydrogel copolymeric material) 5 to 50 percent, preferably 10 to 25, by weight of one or more silicone macromonomers, 5 to 75 percent, preferably 30 to 60 percent, by weight of one or more polysiloxanylalkyl (meth)acrylic monomers, and 10 to 50 percent, preferably 20 to 40 percent, by weight of a hydrophilic monomer. In general, the silicone macromonomer is a poly(organosiloxane) capped with an unsaturated group at two or more ends of the molecule. In addition to the end groups in the above structural formulas, U.S. Pat. No. 4,153,641 to Deichert et al. discloses additional unsaturated groups, including acryloxy or methacryloxy. Fumarate-containing materials such as those taught in U.S. Pat. Nos. 5,512,205; 5,449,729; and 5,310,779 to Lai are also useful substrates in accordance with the invention. Preferably, the silane macromonomer is a silicone-containing vinyl carbonate or vinyl carbamate or a polyurethane-polysiloxane having one or more hard-soft-hard blocks and end-capped with a hydrophilic monomer.
  • Specific examples of contact lens materials for which the present invention is useful are taught in U.S. Pat. No. 6,891,010 (Kunzler et al.); U.S. Pat. No. 5,908,906 (Kunzler et al.); U.S. Pat. No. 5,714,557 (Kunzler et al.); U.S. Pat. No. 5,710,302 (Kunzler et al.); U.S. Pat. No. 5,708,094 (Lai et al.); U.S. Pat. No. 5,616,757 (Bambury et al.); U.S. Pat. No. 5,610,252 (Bambury et al.); U.S. Pat. No. 5,512,205 (Lai); U.S. Pat. No. 5,449,729 (Lai); U.S. Pat. No. 5,387,662 (Kunzler et al.); U.S. Pat. No. 5,310,779 (Lai); and U.S. Pat. No. 5,260,000 (Nandu et al.), the disclosures of which are incorporated herein by reference.
  • Generally, the monomer mixtures may be charged to a mold, and then subjected to heat and/or light radiation, such as UV radiation, to effect curing, or free radical polymerization, of the monomer mixture in the mold. Various processes are known for curing a monomeric mixture in the production of contact lenses or other biomedical devices, including spincasting and static casting. Additionally, the monomer mixtures may be cast in the shape of rods or buttons, which are then lathe cut into a desired shape, for example, into a lens-shaped article.
  • Following casting of the lens, the article may be extracted to remove undesired extractables from the device. For example, in the case of contact lenses made from a silicone hydrogel copolymer, extractables include any remaining diluent, unreacted monomers, and oligomers formed from side reactions of the monomers.
  • Then, the lens is hydrated, either as part of the extraction process, or in a separate subsequent operation. For example, if an organic solvent is used to extract the lens, then the lens is hydrated to replace the organic solvent with water or aqueous solution. Hydration may be performed while the lens is held in its package, or prior to placing the lens in the package. In any event, ultimately, the lens is contained in the package with an aqueous packaging solution.
  • This invention recognized the desirability of effecting attachment of the treatment agent to the lens surfaces while the lens is contained in a package, in contrast to effecting attachment prior to placing the lens in the package. This offers a reduction in material handling steps and the accompanying costs associated therewith. Also, if the solution containing the treatment agent is ophthalmically compatible, this solution may serve as the final packaging solution, and the heat sterilization of the package and its contents can serve to effect chemical attachment of the treatment agent to the lens surfaces.
  • As used herein, “attachment” of the treatment agent to the lens surface, and like terms, denotes that the treatment agent is substantially adhered to the lens surfaces. Thus, after a single rinsing with water of the lens surfaces with the treatment agent attached thereto, at least 50% of the treatment agent will remain adhered to the lens surfaces.
  • It is preferred that the surface treatment agent is attached to the lens surfaces by at least one of covalent bonding, ionic attachment, and hydrogen bonding. Covalent bonding denotes that a chemical reaction occurs between the treatment agent and the lens surface, so that covalent bonds are formed therebetween. Ionic attachment denotes that the lens surfaces are ionically charged, and the organic surface treatment agent contains moieties with an opposite, ionic charge. As an example the lens surfaces may be anionic charged, and the treatment agent may be cationic or zwitterionic, that interacts with the anionic lens surface.
  • A wide variety of organic surface treatment agents may be employed, including treatment agents known in the art.
  • As a first example, this invention is applicable for the organic surface treatment agents described in U.S. Pat. No. 7,083,646, the entire disclosure of which is incorporated herein by reference. Generally, this method involves surface modification of medical devices, particularly ophthalmic lenses, with one or more reactive, hydrophilic polymers as the surface treatment agent. The reactive, hydrophilic polymers are copolymers of at least one hydrophilic monomer and at least one monomer that contains reactive chemical functionality. The hydrophilic monomers can be aprotic types such as N,N-dimethylacrylamide and N-vinylpyrrolidone, or protic types such as methacrylic acid and 2-hydroxyethyl methacrylate. The monomer containing reactive chemical functionality can be an epoxide-containing monomer, such as glycidyl methacrylate. The hydrophilic monomer and the monomer containing reactive chemical functionality are copolymerized at a desired molar ratio thereof. The hydrophilic monomer serves to render the resultant copolymer hydrophilic. The monomer containing reactive chemical functionality provides a reactive group that can react with the lens surface. In other words, this resultant copolymer contains the reactive chemical functionality that can react with complementary functional groups at or near the lens surface, and form covalent bonds therewith.
  • As a second example, this invention is applicable for the organic surface treatment agents described in US 2007/0122540, the entire disclosure of which is incorporated herein by reference. Generally, this method involves surface modification of medical devices, particularly ophthalmic lenses, where reactive surfactants as the surface treatment agent are covalently bound to the lens surfaces. Preferred reactive surfactants are functionalized poloxamers or functionalized poloxamines having reactive functionality that is complimentary to surface functionality of the ophthalmic lens. Representative functionalized surfactants are those containing epoxide, methacrylate, or isocyanate functionalities, such as represented below.
  • Figure US20090145086A1-20090611-C00011
  • For the aforementioned methods where the surface treatment agent is covalently bonded to the lens surface, the reactive groups of the treatment agent are matched with the reactive groups on the lens surface. For example, if the lens surfaces contain carboxylic acid groups, a glycidyl group can be a reactive group of the surface treatment agent. If the lens surfaces contain hydroxy or amino functionality, an isocyanate group or carbonyl chloride group can be a reactive group of the surface treatment agent. A wide variety of suitable combinations of reactive groups will be apparent to those of ordinary skill in the art.
  • Examples of suitable lens-forming monomers, providing reactive groups on the lens surface, include those having hydroxy functional groups, such as 2-hydroxyethyl methacrylate, glyceryl methacrylate and 3-hydroxypropyl methacrylamide. Examples of suitable lens-forming monomers providing the lens surfaces with carboxylic acid reactive groups include methacrylic acid, acrylic acid and N-carboxy-β-alanine-N-vinyl ester. Examples of suitable lens-forming monomers providing the lens surface with oxazolinone reactive groups include 2-isopropenyl-4,4-dimethyl-2-oxazolin-5-one, 2-vinyl-4,4-dimethyl-2-oxazolin-5-one, spiro-4′-(2′-isopropenyl-2′-oxazolin-5-one)cyclohexane, spiro-4′-(2′-vinyl-2′-oxazolin-5′-one)cyclohexane and 2-(1-propenyl)-4,4-dimethyl-oxazolin-5-one. Examples of suitable lens-forming monomers providing the lens surface with anhydride functional groups include methacrylic anhydride, maleic anhydride and acrylic anhydride. An example of a suitable lens-forming monomer providing the lens surfaces with epoxide reactive groups includes glycidyl methacrylate.
  • As another example, the surface treatment agent may be one as employed in the method described in U.S. Pat. No. 6,428,839 (Kunzler et al.), the entire disclosure of which is incorporated herein by reference. Generally, this method employs poly(acrylic)acid (PAA) surface complexation. Hydrogel contact lens copolymers containing polymerized hydrophilic lens-forming monomers having relatively strong proton donating moieties, for example DMA or NVP, are treated with water-based solutions containing PAA or PAA co-polymers, acting as wetting agents, to render a lubricious, stable, highly wettable PAA-based surface coating. Alternately, other proton-donating wetting agents besides PAA-containing agents may be employed, although generally, coating materials containing carboxylic acid functionality are preferred. Surface treatment agents include poly(vinylpyrrolidinone(VP)-co-acrylic acid(AA)), poly(methylvinylether-alt-maleic acid), poly(acrylic acid-graft-ethyleneoxide), poly(AA-co-methacrylic acid), poly(acrylamide-co-AA), poly(AA-co-maleic), and poly(butadiene-maleic acid). Particularly preferred polymers are characterized by acid contents of at least about 30 mole percent, preferably at least about 40 mole percent. The lens, with its surface in contact with the PAA-containing solution, may be heated by autoclaving, or subjected to microwave radiation, to facilitate attachment of the PAA to the lens surface.
  • Other organic surface treatment agents will be apparent to one skilled in the art.
  • There are various variations of the sequence of steps employed in the methods of this invention.
  • As a first example, after placing the lens and the solution containing the treatment agent in the recess of the package, the recess is sealed with the lidstock without removing the solution. In other words, according to this embodiment, this solution also serves as the final packaging solution, and this solution is ophthalmically compatible. Then, when the package contents are heat sterilized, this heat treatment can serve to effect chemical attachment of the treatment agent to the lens surfaces, if needed. Any excess treatment agent, not attached to the lens surfaces, remains in the final packaging solution.
  • As a second example, after placing the lens and the solution containing the treatment agent in the recess of the package, this solution is removed with a portion of the organic treatment agent remaining attached to the lens surface. Any excess treatment agent is removed with the solution. If heat treatment is needed to effect chemical attachment of the treatment agent to the lens surfaces, the heat treatment is performed prior to removing this solution from the package recess. Subsequently, after removing this solution, an aqueous packaging solution is added to the recess, followed by sealing the recess with lidstock and sterilizing the package contents.
  • The final packaging solution is an aqueous solution, preferably a saline solution. having a pH value within the range of about 6 to about 8, and preferably about 6.5 to about 7.8. Suitable buffers may be included, such as: phosphate; borate; citrate; carbonate; tris-(hydroxymethyl)aminomethane (TRIS); bis(2-hydroxyethyl)-imino-tris-(hydroxymethyl)aminoalcohol (bis-tris); zwitterionic buffers such as N-[2-Hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine (Tricine)and N-[2-Hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine, MOPS; N-(Carbamoylmethyl)taurine (ACES); amino acids and amino acid derivatives; and mixtures thereof. Generally, buffers will be used in amounts ranging from about 0.05 to about 2.5 percent by weight, and preferably from about 0.1 to about 1.5 percent by weight of the solution. If needed, the solutions of the present invention may be adjusted with tonicity agents, to approximate the osmotic pressure of normal lacrimal fluids, which is equivalent to a 0.9 percent solution of sodium chloride or 2.5 percent of glycerol solution. The solutions are made substantially isotonic with physiological saline used alone or in combination, otherwise if simply blended with sterile water and made hypotonic or made hypertonic the lenses will lose their desirable optical parameters. Correspondingly, excess saline may result in the formation of a hypertonic solution, which will cause stinging, and eye irritation. Examples of suitable tonicity adjusting agents include, but are not limited to, sodium and potassium chloride, dextrose, calcium and magnesium chloride and the like and mixtures thereof. These agents are typically used individually in amounts ranging from about 0.01 to about 2.5% w/v and preferably from about 0.2 to about 1.5% w/v. Preferably, the tonicity agent will be employed in an amount to provide a final osmotic value of at least about 200 mOsm/kg, preferably from about 200 to about 450 mOsm/kg, more preferably from about 250 to about 400 mOsm/kg, and most preferably from about 280 to about 370 mOsm/kg.
  • Representative blister packages that may be employed in the method of this invention are illustrated in FIGS. 1 to 9.
  • FIGS. 1 to 4 illustrate a first embodiment of a blister package. Package 1 includes a substrate 3 including recess 2 formed therein, recess 2 sized and configured to hold an individual contact lens 5 therein. In the illustrated embodiment, recess 2 is a concave recess with a flat bottom 6. Bottom 6 includes three parallel, longitudinal ridges 7 thereon. Ridges 7 preferably have a height of at least 0.2 mm, more preferably at least 0.4 mm. As seen in FIG. 4, the anterior surface of contact lens 5 rests on at least one of ridges 7 when the package is oriented as in FIG. 4. Without these ridges, the anterior lens surface would rest on flat bottom 6, which could lead to non-uniform coating of the contact lens, especially this anterior surface of the lens.
  • After contacting the contact lens with the treatment agent solution, contact lens 5 is contained in recess 2 and immersed in solution. Recess 2 is then sealed with lidstock, i.e., by sealing the lidstock with heat to raised surface 9. The package and its contents may now be sterilized, preferably by heat sterilization such as autoclaving. Recess 2 has a depth greater than a height of the lens, and a sufficiently large volume, that the lens is completely immersed in the final packaging solution.
  • FIG. 5 illustrates a second embodiment of a blister package. Package 11 includes a substrate 13 including recess 12 formed therein. In this illustrated embodiment, recess 12 has a somewhat oval-shaped flat bottom 16, and the bottom includes four longitudinal ridges 17 thereon.
  • FIGS. 6 and 7 illustrates a third embodiment of a blister package. Package 21 includes a substrate 23 including recess 22 formed therein. In this illustrated embodiment, recess 22 is a concave recess, i.e., a rounded bowl shape. The bottom includes five parallel, longitudinal ridges 27 thereon.
  • FIGS. 8 and 9 illustrates a fourth embodiment of a blister package. Package 31 includes a substrate 33 including recess 32 formed therein. In this illustrated embodiment, recess 32 is a concave recess, i.e., a rounded bowl shape, with multiple raised, dot-like protrusions thereon.
  • Once the package recess contains the contact lens immersed in the final packaging solution, the recess is then sealed with lidstock, i.e., by sealing the lidstock with heat. As an example, the lidstock is sealed to raised surface 9 in FIGS. 1 to 4. The package and its contents may now be sterilized, preferably by heat sterilization such as autoclaving. The recess has a depth greater than a height of the lens, and a sufficiently large volume, that the lens is completely immersed in the final packaging solution. Preferably, the recess is filed with at least 0.5 ml of final packaging solution, more preferably at least 1 ml, and most preferably at least 1.2 ml.
  • While there is shown and described herein certain specific structures and compositions and method steps of the present invention, it will be apparent to those skilled in the art that various modifications may be made without departing from the spirit and scope of the underlying inventive concept and that the same is not limited to particular structures herein shown and described except insofar as indicated by the scope of the appended claims.

Claims (18)

1. A method of treating an ophthalmic lens in a package, comprising:
placing the lens and an aqueous solution in a recess of package, the solution comprising an organic surface treatment agent that attaches to anterior and posterior surfaces of the lens; and
sealing the recess of the package with lidstock and sterilizing the package contents;
wherein a bottom of the recess includes raised projections.
2. The method of claim 1, wherein the surface treatment agent attaches to the lens surfaces by at least one of covalent bonding, ionic attachment, and hydrogen bonding.
3. The method of claim 1, wherein the surface treatment agent attaches to the lens surfaces by covalent bonding.
4. The method of claim 1, wherein the lens surfaces are ionically charged, and the surface treatment agent has an opposite, ionic charge.
5. The method of claim 1, wherein the package contents are sterilized by autoclaving, and autoclaving effects attachment of the surface treatment agent to the lens surfaces.
6. The method of claim 1, wherein attachment of the surface treatment agent is effected by heating the solution while in contact with the lens surfaces in the recess.
7. The method of claim 1, wherein the anterior surface of the lens contacts a portion of the raised projections.
8. The method of claim 1, wherein the projections have a height of at least 0.2 mm.
9. The method of claim 8, wherein the projections have a height of at least 0.4 mm.
10. The method of claim 1, wherein the recess has a depth greater than a height of the lens, and a sufficient volume of solution is placed in the recess so that the lens is completely immersed in the solution.
11. The method of claim 10, where the volume of the solution is at least 0.5 ml.
12. The method of claim 11, where the volume of the solution is at least 1 ml.
13. The method of claim 1, wherein the lens is a hydrogel contact lens.
14. The method of claim 1, wherein the lens is a silicone hydrogel contact lens.
15. The method of claim 1, wherein after placing the lens and the solution in the recess of the package, the recess is sealed with the lidstock without removing the solution.
16. The method of claim 1, wherein after placing the lens and the solution in the recess of the package, the solution is removed with a portion of the surface treatment agent remaining attached to the lens surface, and an aqueous packaging solution is added to the recess prior to sealing the recess with lidstock.
17. The method of claim 1, wherein the bottom includes several parallel, longitudinal projections thereon.
18. The method of claim 1, wherein the bottom includes several raised dot-like bumps.
US12/244,333 2007-12-11 2008-10-02 Method for treating ophthalmic lenses Abandoned US20090145086A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/244,333 US20090145086A1 (en) 2007-12-11 2008-10-02 Method for treating ophthalmic lenses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1285507P 2007-12-11 2007-12-11
US12/244,333 US20090145086A1 (en) 2007-12-11 2008-10-02 Method for treating ophthalmic lenses

Publications (1)

Publication Number Publication Date
US20090145086A1 true US20090145086A1 (en) 2009-06-11

Family

ID=40373432

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/244,333 Abandoned US20090145086A1 (en) 2007-12-11 2008-10-02 Method for treating ophthalmic lenses

Country Status (2)

Country Link
US (1) US20090145086A1 (en)
WO (1) WO2009076029A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110062607A1 (en) * 2009-09-11 2011-03-17 Julie Clements Methods, devices, and systems for moving wet ophthalmic lenses during their manufacture
WO2012016098A1 (en) 2010-07-30 2012-02-02 Novartis Ag A silicone hydrogel lens with a crosslinked hydrophilic coating
WO2013074535A1 (en) 2011-11-15 2013-05-23 Novartis Ag A silicone hydrogel lens with a crosslinked hydrophilic coating
WO2014093299A1 (en) 2012-12-11 2014-06-19 Novartis Ag Method for applying a coating onto a silicone hydrogel lens
US9005700B2 (en) 2011-10-12 2015-04-14 Novartis Ag Method for making UV-absorbing ophthalmic lenses
WO2015095157A1 (en) 2013-12-17 2015-06-25 Novartis Ag A silicone hydrogel lens with a crosslinked hydrophilic coating
WO2016032926A1 (en) 2014-08-26 2016-03-03 Novartis Ag Method for applying stable coating on silicone hydrogel contact lenses
US9422447B2 (en) 2012-06-14 2016-08-23 Novartis Ag Azetidinium-containing copolymers and uses thereof
WO2016145204A1 (en) 2015-03-11 2016-09-15 University Of Florida Research Foundation, Inc. Mesh size control of lubrication in gemini hydrogels
WO2017037610A1 (en) 2015-09-04 2017-03-09 Novartis Ag Method for producing contact lenses with durable lubricious coatings thereon
WO2017093834A1 (en) 2015-12-03 2017-06-08 Novartis Ag Contact lens packaging solutions
WO2017103793A1 (en) 2015-12-15 2017-06-22 Novartis Ag Method for applying stable coating on silicone hydrogel contact lenses
US9720138B2 (en) 2014-08-26 2017-08-01 Novartis Ag Poly(oxazoline-co-ethyleneimine)-epichlorohydrin copolymers and uses thereof
WO2018078598A1 (en) 2016-10-31 2018-05-03 Chnovartis Ag Method for producing surface coated contact lenses with wearing comfort
US10081142B2 (en) 2015-12-15 2018-09-25 Novartis Ag Method for producing contact lenses with a lubricious surface
WO2018224975A1 (en) 2017-06-07 2018-12-13 Novartis Ag Silicone hydrogel contact lenses
US10338408B2 (en) 2012-12-17 2019-07-02 Novartis Ag Method for making improved UV-absorbing ophthalmic lenses
US10809181B2 (en) 2017-08-24 2020-10-20 Alcon Inc. Method and apparatus for determining a coefficient of friction at a test site on a surface of a contact lens
US10830923B2 (en) 2017-12-13 2020-11-10 Alcon Inc. Method for producing MPS-compatible water gradient contact lenses
US10875967B2 (en) 2017-06-07 2020-12-29 Alcon Inc. Silicone hydrogel contact lenses
WO2021090169A1 (en) 2019-11-04 2021-05-14 Alcon Inc. Contact lenses with surfaces having different softness
US11008413B1 (en) 2017-03-18 2021-05-18 Verily Life Sciences Llc Biocompatible materials for underlid device fabrication
WO2021124099A1 (en) 2019-12-16 2021-06-24 Alcon Inc. Wettable silicone hydrogel contact lenses
WO2022023966A1 (en) 2020-07-28 2022-02-03 Alcon Inc. Contact lenses with softer lens surfaces
EP4079496A1 (en) * 2021-04-16 2022-10-26 Pegavision Corporation Contact lens and manufacturing method thereof
WO2022224169A1 (en) 2021-04-22 2022-10-27 Alcon Inc. Method for applying a coating onto a non-silicone hydrogel lens
WO2024038390A1 (en) 2022-08-17 2024-02-22 Alcon Inc. A contact lens with a hydrogel coating thereon

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321261A (en) * 1978-01-05 1982-03-23 Polymer Technology Corporation Ionic ophthalmic solutions
US5145643A (en) * 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5192316A (en) * 1988-02-16 1993-03-09 Allergan, Inc. Ocular device
US5451237A (en) * 1993-11-10 1995-09-19 Vehige; Joseph G. Compositions and methods for inhibiting and reducing lysozyme deposition on hydrophilic contact lenses using biocompatible colored compounds
US5580392A (en) * 1994-04-05 1996-12-03 Allergan Contact lens cleaning compositions with particles of variable hardness and processes of use
US5958194A (en) * 1997-09-18 1999-09-28 Glazier; Alan N. Gas permeable elastomer contact lens bonded with titanium and/or oxides thereof
US20030109390A1 (en) * 1997-06-06 2003-06-12 Bausch & Lomb Incorporated Contact lens packing solutions
US20050126940A1 (en) * 2002-08-12 2005-06-16 Makoto Nakagawa Hydrating case for moisture-containing lens and hydrating method using it
US20050133382A1 (en) * 2003-12-22 2005-06-23 Milt Gerard Contact lens holder
US20050226488A1 (en) * 2004-03-31 2005-10-13 Paud Barry Inspection system for blister packages
US6958169B2 (en) * 2002-12-17 2005-10-25 Bausch & Lomb Incorporated Surface treatment of medical device
US20070149428A1 (en) * 2005-12-14 2007-06-28 Bausch & Lomb Incorporated Method of Packaging a Lens
US20080110770A1 (en) * 2006-11-10 2008-05-15 Bausch & Lomb Incorporated Packaging solutions
US20090145091A1 (en) * 2007-12-11 2009-06-11 Richard Connolly Method for treating ophthalmic lenses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428839B1 (en) * 2000-06-02 2002-08-06 Bausch & Lomb Incorporated Surface treatment of medical device
US20040004008A1 (en) * 2002-06-26 2004-01-08 Peck James M. Contact lens packages
AR055909A1 (en) * 2005-04-15 2007-09-12 Johnson & Johnson Vision Care METHOD AND APPLIANCES FOR SEALING OPTICAL LENS PACKS

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321261A (en) * 1978-01-05 1982-03-23 Polymer Technology Corporation Ionic ophthalmic solutions
US5192316A (en) * 1988-02-16 1993-03-09 Allergan, Inc. Ocular device
US5145643A (en) * 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5451237A (en) * 1993-11-10 1995-09-19 Vehige; Joseph G. Compositions and methods for inhibiting and reducing lysozyme deposition on hydrophilic contact lenses using biocompatible colored compounds
US5580392A (en) * 1994-04-05 1996-12-03 Allergan Contact lens cleaning compositions with particles of variable hardness and processes of use
US20030109390A1 (en) * 1997-06-06 2003-06-12 Bausch & Lomb Incorporated Contact lens packing solutions
US5958194A (en) * 1997-09-18 1999-09-28 Glazier; Alan N. Gas permeable elastomer contact lens bonded with titanium and/or oxides thereof
US20050126940A1 (en) * 2002-08-12 2005-06-16 Makoto Nakagawa Hydrating case for moisture-containing lens and hydrating method using it
US6958169B2 (en) * 2002-12-17 2005-10-25 Bausch & Lomb Incorporated Surface treatment of medical device
US20050133382A1 (en) * 2003-12-22 2005-06-23 Milt Gerard Contact lens holder
US20050226488A1 (en) * 2004-03-31 2005-10-13 Paud Barry Inspection system for blister packages
US20070149428A1 (en) * 2005-12-14 2007-06-28 Bausch & Lomb Incorporated Method of Packaging a Lens
US20080110770A1 (en) * 2006-11-10 2008-05-15 Bausch & Lomb Incorporated Packaging solutions
US20090145091A1 (en) * 2007-12-11 2009-06-11 Richard Connolly Method for treating ophthalmic lenses

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110062607A1 (en) * 2009-09-11 2011-03-17 Julie Clements Methods, devices, and systems for moving wet ophthalmic lenses during their manufacture
US9296160B2 (en) * 2009-09-11 2016-03-29 Coopervision International Holding Company, Lp Method for moving wet ophthalmic lenses during their manufacture
US10953615B2 (en) 2009-09-11 2021-03-23 Coopervision International Limited Methods and devices for moving wet ophthalmic lenses during their manufacture
US9738813B2 (en) 2010-07-30 2017-08-22 Novartis Ag Silicone hydrogel lens with a crosslinked hydrophilic coating
US8529057B2 (en) 2010-07-30 2013-09-10 Novartis Ag Silicone hydrogel lens with a crosslinked hydrophilic coating
US9816009B2 (en) 2010-07-30 2017-11-14 Novartis Ag Silicone hydrogel lenses with water-rich surfaces
US8939577B2 (en) 2010-07-30 2015-01-27 Novartis Ag Silicone hydrogel lenses with water-rich surfaces
US8944592B2 (en) 2010-07-30 2015-02-03 Novartis Ag Silicone hydrogel lens with a crosslinked hydrophilic coating
US8480227B2 (en) 2010-07-30 2013-07-09 Novartis Ag Silicone hydrogel lenses with water-rich surfaces
US9239409B2 (en) 2010-07-30 2016-01-19 Novartis Ag Silicone hydrogel lens with a crosslinked hydrophilic coating
US9244200B2 (en) 2010-07-30 2016-01-26 Novartis Ag Silicone hydrogel lenses with water-rich surfaces
US10781340B2 (en) 2010-07-30 2020-09-22 Alcon Inc. Silicone hydrogel lenses with water-rich surfaces
WO2012016098A1 (en) 2010-07-30 2012-02-02 Novartis Ag A silicone hydrogel lens with a crosslinked hydrophilic coating
US9411171B2 (en) 2010-07-30 2016-08-09 Novartis Ag Silicone hydrogel lenses with water-rich surfaces
US9507173B2 (en) 2010-07-30 2016-11-29 Novartis Ag Silicone hydrogel lens with a crosslinked hydrophilic coating
US9005700B2 (en) 2011-10-12 2015-04-14 Novartis Ag Method for making UV-absorbing ophthalmic lenses
US9505184B2 (en) 2011-11-15 2016-11-29 Novartis Ag Silicone hydrogel lens with a crosslinked hydrophilic coating
WO2013074535A1 (en) 2011-11-15 2013-05-23 Novartis Ag A silicone hydrogel lens with a crosslinked hydrophilic coating
US9422447B2 (en) 2012-06-14 2016-08-23 Novartis Ag Azetidinium-containing copolymers and uses thereof
US10100219B2 (en) 2012-06-14 2018-10-16 Novartis Ag Azetidinium-containing copolymers and uses thereof
US9575332B2 (en) 2012-12-11 2017-02-21 Novartis Ag Method for applying a coating onto a silicone hydrogel lens
WO2014093299A1 (en) 2012-12-11 2014-06-19 Novartis Ag Method for applying a coating onto a silicone hydrogel lens
US10338408B2 (en) 2012-12-17 2019-07-02 Novartis Ag Method for making improved UV-absorbing ophthalmic lenses
WO2015095157A1 (en) 2013-12-17 2015-06-25 Novartis Ag A silicone hydrogel lens with a crosslinked hydrophilic coating
US9708087B2 (en) 2013-12-17 2017-07-18 Novartis Ag Silicone hydrogel lens with a crosslinked hydrophilic coating
US9720138B2 (en) 2014-08-26 2017-08-01 Novartis Ag Poly(oxazoline-co-ethyleneimine)-epichlorohydrin copolymers and uses thereof
US11002884B2 (en) 2014-08-26 2021-05-11 Alcon Inc. Method for applying stable coating on silicone hydrogel contact lenses
WO2016032926A1 (en) 2014-08-26 2016-03-03 Novartis Ag Method for applying stable coating on silicone hydrogel contact lenses
WO2016145204A1 (en) 2015-03-11 2016-09-15 University Of Florida Research Foundation, Inc. Mesh size control of lubrication in gemini hydrogels
US10723842B2 (en) 2015-03-11 2020-07-28 University Of Florida Research Foundation, Inc. Mesh size control of lubrication in gemini hydrogels
US9810812B2 (en) 2015-09-04 2017-11-07 Novartis Ag Method for producing contact lenses with durable lubricious coatings thereon
WO2017037610A1 (en) 2015-09-04 2017-03-09 Novartis Ag Method for producing contact lenses with durable lubricious coatings thereon
US9829723B2 (en) 2015-12-03 2017-11-28 Novartis Ag Contact lens packaging solutions
EP3543004A1 (en) 2015-12-03 2019-09-25 Novartis AG Contact lens packaging solutions
WO2017093834A1 (en) 2015-12-03 2017-06-08 Novartis Ag Contact lens packaging solutions
WO2017103793A1 (en) 2015-12-15 2017-06-22 Novartis Ag Method for applying stable coating on silicone hydrogel contact lenses
US10449740B2 (en) 2015-12-15 2019-10-22 Novartis Ag Method for applying stable coating on silicone hydrogel contact lenses
US10081142B2 (en) 2015-12-15 2018-09-25 Novartis Ag Method for producing contact lenses with a lubricious surface
US10718960B2 (en) 2016-10-31 2020-07-21 Alcon Inc. Method for producing contact lenses with wearing comfort
WO2018078598A1 (en) 2016-10-31 2018-05-03 Chnovartis Ag Method for producing surface coated contact lenses with wearing comfort
US11008413B1 (en) 2017-03-18 2021-05-18 Verily Life Sciences Llc Biocompatible materials for underlid device fabrication
US10866344B2 (en) 2017-06-07 2020-12-15 Alcon Inc. Silicone hydrogel contact lenses
US10875967B2 (en) 2017-06-07 2020-12-29 Alcon Inc. Silicone hydrogel contact lenses
WO2018224975A1 (en) 2017-06-07 2018-12-13 Novartis Ag Silicone hydrogel contact lenses
EP4235274A2 (en) 2017-06-07 2023-08-30 Alcon Inc. Silicone hydrogel contact lenses
EP3928967A1 (en) 2017-06-07 2021-12-29 Alcon Inc. Silicone hydrogel contact lenses
US10809181B2 (en) 2017-08-24 2020-10-20 Alcon Inc. Method and apparatus for determining a coefficient of friction at a test site on a surface of a contact lens
US11256003B2 (en) 2017-12-13 2022-02-22 Alcon Inc. Weekly and monthly disposable water gradient contact lenses
US10830923B2 (en) 2017-12-13 2020-11-10 Alcon Inc. Method for producing MPS-compatible water gradient contact lenses
US11029446B2 (en) 2017-12-13 2021-06-08 Alcon Inc. Method for producing MPS-compatible water gradient contact lenses
US11029447B2 (en) 2017-12-13 2021-06-08 Alcon Inc. Method for producing MPS-compatible water gradient contact lenses
WO2021090169A1 (en) 2019-11-04 2021-05-14 Alcon Inc. Contact lenses with surfaces having different softness
US11513257B2 (en) 2019-12-16 2022-11-29 Alcon Inc. Wettable silicone hydrogel contact lenses
WO2021124099A1 (en) 2019-12-16 2021-06-24 Alcon Inc. Wettable silicone hydrogel contact lenses
WO2022023966A1 (en) 2020-07-28 2022-02-03 Alcon Inc. Contact lenses with softer lens surfaces
EP4079496A1 (en) * 2021-04-16 2022-10-26 Pegavision Corporation Contact lens and manufacturing method thereof
JP2022164588A (en) * 2021-04-16 2022-10-27 ペガヴィジョン コーポレーション Contact lens and manufacturing method therefor
WO2022224169A1 (en) 2021-04-22 2022-10-27 Alcon Inc. Method for applying a coating onto a non-silicone hydrogel lens
WO2024038390A1 (en) 2022-08-17 2024-02-22 Alcon Inc. A contact lens with a hydrogel coating thereon

Also Published As

Publication number Publication date
WO2009076029A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
US20090145086A1 (en) Method for treating ophthalmic lenses
US20090145091A1 (en) Method for treating ophthalmic lenses
US9910190B2 (en) Poly(oxazoline-co-ethyleneimine)-epichlorohydrin copolymers and uses thereof
JP4712265B2 (en) contact lens
US8490782B2 (en) Packaging solutions
US7919136B2 (en) Surface treatment of biomedical devices
US7837934B2 (en) Packaging solutions
JP5689418B2 (en) Ionic silicone hydrogels with improved hydrolytic stability
JP6165714B2 (en) Medical device having uniform charge density and method of manufacturing the same
US8454689B2 (en) Brush copolymers
ES2372010T3 (en) PACKING SOLUTIONS.
US8631631B2 (en) Packaging solutions
US9101667B2 (en) Ionic silicone hydrogels comprising pharmaceutical and/or neuticeutical components and having improved hydrolytic stability
US20080151180A1 (en) Coatings and Solutions for Contact Lenses
US20100149482A1 (en) Contact lens
US20090108479A1 (en) Method for Making Biomedical Devices
US20090142485A1 (en) Process for Making Biomedical Devices
US20080151181A1 (en) Coatings and Solutions for Contact Lenses
US20100168356A1 (en) Biomedical Devices
US20090173643A1 (en) Packaging Solutions
US7884141B2 (en) Biomedical devices
EP4165446B1 (en) Imidazolium zwitterion polymerizable compounds and ophthalmic devices incorporating them
US20210388142A1 (en) Amino acid-based polymerizable compounds and ophthalmic devices prepared therefrom
US20090156745A1 (en) Surface modified biomedical devices
US20210388141A1 (en) Imidazolium zwitterion polymerizable compounds and ophthalmic devices incorporating them

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION